SETD2 and cancer: To investigate whether these distinct characterisitics of SETD2 mutation could translate into cancer prognosis, we compared the OS (P = 0.38, Fig. 1i), disease-free survival (P = 0.53, Fig. 1j), disease-specific survival (P = 0.76, Fig. 1k), and progress-free survival (P = 0.96, Fig. 1l) between patients with SETD2 mutant cancer and patients with SETD2 nonmutant cancer.